NO751117L - - Google Patents
Info
- Publication number
- NO751117L NO751117L NO751117A NO751117A NO751117L NO 751117 L NO751117 L NO 751117L NO 751117 A NO751117 A NO 751117A NO 751117 A NO751117 A NO 751117A NO 751117 L NO751117 L NO 751117L
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- solution
- agent
- surfactant
- urea
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 claims description 117
- 108010050904 Interferons Proteins 0.000 claims description 117
- 229940079322 interferon Drugs 0.000 claims description 116
- 230000000694 effects Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
- 239000004202 carbamide Substances 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 19
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 16
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 16
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 125000000129 anionic group Chemical group 0.000 claims description 9
- 239000003945 anionic surfactant Substances 0.000 claims description 8
- 239000003093 cationic surfactant Substances 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 29
- 230000007420 reactivation Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000002779 inactivation Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000711404 Avian avulavirus 1 Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical compound CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7404590A NL7404590A (nl) | 1974-04-03 | 1974-04-03 | Werkwijze voor het reactiveren van interferon. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO751117L true NO751117L (uk) | 1975-10-06 |
Family
ID=19821110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO751117A NO751117L (uk) | 1974-04-03 | 1975-04-02 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4017600A (uk) |
| JP (1) | JPS5191319A (uk) |
| AU (1) | AU7951075A (uk) |
| BE (1) | BE826890A (uk) |
| DE (1) | DE2514536A1 (uk) |
| DK (1) | DK139875A (uk) |
| FI (1) | FI750952A (uk) |
| FR (1) | FR2266741B3 (uk) |
| IT (1) | IT1045540B (uk) |
| NL (1) | NL7404590A (uk) |
| NO (1) | NO751117L (uk) |
| SE (1) | SE7503770L (uk) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
| US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| IN150740B (uk) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| US6410697B1 (en) | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
| US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| EP0077063B1 (en) * | 1981-10-13 | 1988-03-16 | Exovir, Inc. | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| US5582824A (en) * | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
| US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
| US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4476049A (en) * | 1983-09-20 | 1984-10-09 | Hoffmann-La Roche Inc. | Method for the extraction of immune interferon |
| US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
| US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
| IL74093A0 (en) * | 1984-01-23 | 1985-04-30 | Takeda Chemical Industries Ltd | Stable composition of gamma-interferon |
| US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
| DE3421302A1 (de) * | 1984-06-08 | 1985-12-12 | Hoechst Ag, 6230 Frankfurt | Verfahren zur isolierung und reinigung von (alpha)-interferonen |
| DE3482307D1 (de) * | 1984-09-21 | 1990-06-28 | Vnii Osobo Cistych Biopreparat | Rektifizierungsverfahren menschlichen leukozyten-interferons. |
| US4950470A (en) * | 1986-10-06 | 1990-08-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing interferon-gamma |
| US4999422A (en) * | 1988-04-15 | 1991-03-12 | Biogen, N.V. | Continuous method of refolding proteins |
| US5165921A (en) * | 1989-01-23 | 1992-11-24 | National Geno Sciences, Inc. | Method for treating condyloma acuminatum with interferon |
| US5236707A (en) * | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL286954A (uk) * | 1962-01-03 |
-
1974
- 1974-04-03 NL NL7404590A patent/NL7404590A/xx not_active Application Discontinuation
-
1975
- 1975-03-20 BE BE1006542A patent/BE826890A/xx unknown
- 1975-03-26 AU AU79510/75A patent/AU7951075A/en not_active Expired
- 1975-03-27 FI FI750952A patent/FI750952A/fi not_active Application Discontinuation
- 1975-04-01 IT IT48873/75A patent/IT1045540B/it active
- 1975-04-02 FR FR7510303A patent/FR2266741B3/fr not_active Expired
- 1975-04-02 SE SE7503770A patent/SE7503770L/xx unknown
- 1975-04-02 DK DK139875A patent/DK139875A/da unknown
- 1975-04-02 NO NO751117A patent/NO751117L/no unknown
- 1975-04-03 JP JP50040755A patent/JPS5191319A/ja active Pending
- 1975-04-03 DE DE19752514536 patent/DE2514536A1/de not_active Withdrawn
- 1975-04-03 US US05/564,726 patent/US4017600A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| SE7503770L (sv) | 1975-10-06 |
| JPS5191319A (en) | 1976-08-10 |
| NL7404590A (nl) | 1975-10-07 |
| BE826890A (nl) | 1975-09-22 |
| DK139875A (uk) | 1975-10-04 |
| AU7951075A (en) | 1976-09-30 |
| FI750952A (uk) | 1975-10-04 |
| DE2514536A1 (de) | 1975-10-09 |
| IT1045540B (it) | 1980-05-10 |
| US4017600A (en) | 1977-04-12 |
| FR2266741B3 (uk) | 1977-12-16 |
| FR2266741A1 (uk) | 1975-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO751117L (uk) | ||
| NO751118L (uk) | ||
| CN1006198B (zh) | γ-球蛋白的病毒灭活热处理方法 | |
| JPS6178730A (ja) | 免疫グロブリンの加熱処理方法 | |
| JPH0761956B2 (ja) | 静注可能な免疫グロブリン | |
| DK156698B (da) | Fremgangsmaade til pasteurisering af et materiale indeholdende et termisk foelsomt, terapeutisk aktivtprotein valgt blandt alfa-l-antitrypsin, antithrombin-iii, praekallikrein, antihaemofil faktor (faktorviii) og fibronectin | |
| KR100186824B1 (ko) | 알부민 제제 및 이의 제조방법 | |
| Castellino et al. | The denaturing effectiveness of guanidinium, carbamoylguanidinium, and guanylguanidinium salts | |
| NO328450B1 (no) | Stabilt farmasøytisk preparat inneholdende faktor VIII | |
| JP4010573B2 (ja) | 低温殺菌中の血漿を安定化するための組成物および治療学的用途のための低温殺菌血漿溶液 | |
| JPS6237010B2 (uk) | ||
| JPS6219406B2 (uk) | ||
| JP2879427B2 (ja) | ウイルスおよびバクテリア汚染物の熱的不活性化中の生物学的および製薬的生成物の安定化 | |
| CA2822229C (en) | Caprylate viral deactivation | |
| US5116950A (en) | Process for heat treating fibrinogen | |
| Cesario et al. | Relationship between the physicochemical nature of human interferon, the cell induced, and the inducing agent | |
| Stewart II et al. | Protective effects of anionic detergents on interferons: reversible denaturation | |
| JPS6122022A (ja) | 血漿蛋白の加熱処理方法 | |
| EP0179075B2 (en) | Virus risk-reduced hemoglobin and method for making same | |
| CN1129139A (zh) | 吡咯类在生物活性蛋白溶液中作为杀病毒剂的用途 | |
| WO1999051279A1 (en) | A method for treating contaminated products and articles | |
| JPH0278633A (ja) | ウイルス不活化方法 | |
| JPS6210019A (ja) | 人血液凝固第９因子含有製剤の加熱処理方法 | |
| JPH04352727A (ja) | 耐熱性の改善された血清アルブミン組成物 | |
| DK157170C (da) | Koncentrat af den anti-hæmofile Faktor VIII samt fremgangsmåde til fremstilling deraf |